Go Deep
REGENXBIO Inc.
REGENXBIO Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 15,189 | -1.9 | 6.68 | 3.49 | 691.40 |
| Oct 2026 | 15,481 | -1.8 | 6.33 | 3.49 | 653.24 |
| Oct 2026 | 15,266 | -2.0 | 6.59 | 3.49 | 679.92 |
| Oct 2026 | 15,446 | -1.8 | 6.37 | 3.49 | 655.90 |
| Oct 2026 | 15,273 | -1.9 | 6.58 | 3.49 | 677.94 |
| Oct 2026 | 15,081 | -2.0 | 6.81 | 3.49 | 701.64 |
| Oct 2026 | 15,258 | -1.9 | 6.59 | 3.49 | 678.15 |
| Oct 2026 | 15,258 | -1.9 | 6.59 | 3.49 | 676.78 |
REGENXBIO Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 108,019,000.0 | 6,393,000.0 | 30,337,000.0 | 29,733,000.0 |
| Net Profit | 22,709,000.0 | -90,051,000.0 | -67,149,000.0 | -61,941,000.0 |
| EPS | 0.4 | -1.7 | -1.3 | -1.2 |
REGENXBIO Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 170,441,000.0 | 83,328,000.0 | 90,242,000.0 | 112,724,000.0 | — |
| Net Profit | -193,878,000.0 | -227,102,000.0 | -263,494,000.0 | -280,321,000.0 | — |
| EPS | -3.8 | -4.6 | -6.0 | -6.5 | — |
REGENXBIO Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 453,032,000.0 | 465,989,000.0 | 573,970,000.0 | 833,268,000.0 | — |
| Total Liabilities | 350,299,000.0 | 206,338,000.0 | 262,228,000.0 | 317,073,000.0 | — |
| Total Equity | 102,733,000.0 | 259,651,000.0 | 311,742,000.0 | 516,195,000.0 | — |
Owes vs Owns
REGENXBIO Inc. owed $0.81 for every $1 it owned in Jun 2026, up from $0.38 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.81× | 0.77× | 0.44× | 0.46× | 0.38× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
REGENXBIO Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 50.8%Receivables 6.0%Fixed assets (tangible) 33.6%Long-term investments 2.4%Other assets 7.2%
How it's funded — Dec 2025
Short-term debt 1.8%Long-term debt 14.4%Payables 4.7%Other liabilities 56.4%Shareholders' equity 22.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 230.1 | 234.7 | 275.3 | 364.6 |
| Receivables | 27.4 | 21.6 | 26.3 | 30.3 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 152.0 | 171.3 | 192.6 | 206.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 10.8 | 10.2 | 38.9 | 200.6 |
| Other assets | 32.8 | 28.3 | 40.9 | 31.0 |
| Liabilities & equity | ||||
| Short-term debt | 8.3 | 7.9 | 7.1 | 6.0 |
| Long-term debt | 65.2 | 74.1 | 82.2 | 88.8 |
| Payables | 21.4 | 22.8 | 22.8 | 27.2 |
| Other liabilities | 255.4 | 101.5 | 150.2 | 195.1 |
| Shareholders' equity | 102.7 | 259.7 | 311.7 | 516.2 |
| Net tangible assets | 102.7 | 259.7 | 311.7 | 516.2 |
REGENXBIO Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -123,963,000.0 | -173,125,000.0 | -218,407,000.0 | -207,488,000.0 | — |
| Investing Activities | -15,868,000.0 | 103,446,000.0 | 190,943,000.0 | -11,929,000.0 | — |
| Financing Activities | 116,771,000.0 | 92,683,000.0 | -34,966,000.0 | -28,840,000.0 | — |